VBI Vaccines (VBIV) & Trillium Therapeutics (TRIL) Head-To-Head Review

VBI Vaccines (NASDAQ: VBIV) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk.

Insider & Institutional Ownership

20.3% of VBI Vaccines shares are owned by institutional investors. Comparatively, 47.2% of Trillium Therapeutics shares are owned by institutional investors. 34.1% of VBI Vaccines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


This table compares VBI Vaccines and Trillium Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VBI Vaccines -4,463.06% -49.17% -37.55%
Trillium Therapeutics N/A -248.39% -65.21%

Risk and Volatility

VBI Vaccines has a beta of 2.32, suggesting that its share price is 132% more volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.

Earnings and Valuation

This table compares VBI Vaccines and Trillium Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
VBI Vaccines $550,000.00 526.72 -$23.20 million N/A N/A
Trillium Therapeutics N/A N/A -$23.96 million ($3.79) -2.52

VBI Vaccines has higher revenue and earnings than Trillium Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings and target prices for VBI Vaccines and Trillium Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VBI Vaccines 0 0 3 0 3.00
Trillium Therapeutics 0 0 3 0 3.00

VBI Vaccines currently has a consensus price target of $10.50, suggesting a potential upside of 131.28%. Trillium Therapeutics has a consensus price target of $12.50, suggesting a potential upside of 30.89%. Given VBI Vaccines’ higher probable upside, analysts clearly believe VBI Vaccines is more favorable than Trillium Therapeutics.


VBI Vaccines beats Trillium Therapeutics on 7 of the 9 factors compared between the two stocks.

About VBI Vaccines

VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.

About Trillium Therapeutics

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Receive News & Ratings for VBI Vaccines Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply